SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY)
INCY 70.33+2.3%3:59 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (3149)9/9/2017 4:09:26 PM
From: tuck  Read Replies (1) of 3202
 
IDO/PD1 . . . Here's is INCY's presentation, which dose give demographic data. This was a dose escalation trial, whereas, NLNK's was at single dose. So apparent disadvantage of Epacadostat I noted in the prior post may be due to that.

Incyte ESMO presentation

I can't quite read through the patient baseline characteristics. It seems ECHO had a slightly higher % of M1c patients: 55 versus 50. Further, every patient was M stage (stage IV), whereas in the NewLink trial, 13% were stage III. ECHO also had substantially fewer treatment naive patients.

So now, having seen all the available data, I would call this approximately even. NLNK had better numbers, but population was less sick.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News